- Cell Therapy
- Gene Therapy
- Exosomes
- Tissue Engineering
- Bioprocessing
Your Path to Therapeutic Commercialization
At RoosterBio, we are experts in radically simplifying the use of adult human mesenchymal stem/stromal cells (hMSCs) to propel the commercialization of therapeutic technologies. By enabling living cells to become more affordable at the lowest cost per million cells with industry leading quality, we make MSCs easier to access and much simpler to incorporate into product development efforts, leading to rapid acceleration in products coming to market that incorporate these technologies.
Research & Optimization
High quality raw materials with built-in processes and protocols make it easy to establish MSCs in new programs.
Product & Process Development
Our complete hMSC systems offer robust and affordable solutions that allow you to focus on your final development goals.
Tech Transfer & Manufacturing
Seamlessly translate into the clinic with off-the-shelf cGMP products and processes that scale alongside you.
Our Scalable Bioprocessing Solutions
No matter your scale, our hMSC and exosome systems with built-in processes significantly shorten development timelines and reduce costs on your journey to clinic and market.
Latest Blog
AgentV’s Virtues at the Vanguard of Extracellular Vesicles
Emerging new therapeutic agents based on extracellular vesicle and/or exosome modalities can offer great hope against unmet clinical needs. Nevertheless, it’s imperative that this nascent drug product class exceeds defined parameters of safety, identity, strength, purity, and quality [...]
Read MoreWhy RoosterBio?
Global Presence
Supports 500+ government, academia, institution, and industry partners from more than 25 countries across 6 continents.
Regulatory Expertise
Our cGMP media and cells, supported by Type II FDA Master Files, are being used as ancillary and raw starting materials for multiple ongoing and planned registered clinical trials.
Thought Leadership
Over 350 peer reviewed journal articles have cited RoosterBio cells and media since 2015.